# ETHANOBENZAZEPINES, A PROCESS AND INTERMEDIATES FOR THEIR PREPARATION AND THEIR USE AS MEDICAMENTS

## Abstract
The present invention relates to ethanobenzazepines of the formula

## Claims
1. A compound of the formula wherein R is hydrogen, halogen or lower alkyl X is C O or CHOH Y is COH or a group of the formula COCOR¹ wherein R¹ is lower alkyl and X and Y taken together with their common bond form a group of the formula wherein R² and R³ are independently hydrogen, lower alkyl or phenyl an optical or geometric isomer thereof or a pharmaceutically acceptable acid addition salt thereof.

## Description
The present invention relates to ethanobenzazepines. More particularly, the present invention relates to ethanobenzazepines of the formula Subgeneric to the ethanobenzazepines of the present invention are compounds wherein The present invention also relates to 4 2 fluoro benzoyl piperidines of the formula As used through the specification and appended claims, the term alkyl refers to a straight or branched chain hydrocarbon radical containing no unsaturation and having 1 to 8 carbon atoms such as methyl, ethyl, 1 propyl, 2 propyl, 1 butyl, 1 pentyl, 2 pentyl,3 hexyl, 4 heptyl, 2 octyl, and the like the term alkoxy refers to a monovalent substituent which consists of an alkyl group linked through an ether oxygen and having its free valence bond from the ether oxygen such as methoxy, ethoxy, proproxy, butoxy, 1,1 dimethylethoxy, pentoxy, 3 methylpentoxy, 2 ethylpentoxy, octoxy, and the like the term alkanol refers to a compound formed by a combination of an alkyl group and a hydroxy radical. Examples of alkanols are methanol, ethanol, 1 and 2 propanol, 2,2 dimethylethanol, hexanol, octanol, and the like. The term alkanoic acid refers to a compound formed by combination of a carboxyl group with a hydrogen atom or alkyl group. Examples of alkanoic acids are formic acid, acetic acid, propionic acid, butanoic acid, pentanoic acid, hexanoic acid, octanoic acid, and the like the term halogen refers to a member of the family consisting of fluorine, bromine or iodine. The term alkanone refers to a compound formed by the combination of a carbonyl group and two alkyl groups. Examples of alkanones are acetone, 2 butanone, 3 pentanone, 3 hexanone, 2 octanone, and the like. The term alkanal refers to a compound formed by the combination of a carbonyl group, an alkyl group and a hydrogen atom. Examples of alkanals are formaldehyde, acetaldehyde, propanol, pentanal, hexanal, octanal, and the like. The term lower as applied to any of the aforementioned groups refers to a group having a carbon skeleton containing up to and including 6 carbon atoms. The compounds of the present invention which lack an element of symmetry exist as optical antipodes and as the racemic forms thereof. The optical antipode may be prepared from the corresponding racemic forms by standard optical resolution techniques, involving, for example, the separation of diasteromeric salts of those instant compounds characterized by the presence of a basic amino group and an optically active acid, or by the synthesis from optically active precursors. The present invention comprehends all optical isomers and racemic forms thereof and all geometric isomers of the compounds disclosed and claimed herein. The formulas of the compounds shown herein are intended to encompass all possible geometric and optical isomers of the compounds so depicted. The novel ethanobenzazepines of the present invention are prepared by the processes illustrated in the Reaction Scheme. To prepare the parent ethanobenzazepine system, i.e., a 1,4 ethano 4 hydroxy 2,3,4,5 tetrahydro 5H 1 benzazepin 5 one To prepare an alkanoyl derivative To synthesize a diol of formula To elaborate the dioxolo function, i.e., to prepare a compound of formula The 2 fluorobenzoyl 4 hydroxypiperidine Thus condensation of the fluorobenzene Alternatively, a fluorobenzene The 1,4 ethanobenzazepines of the present invention are useful as analgetics due to their ability to alleviate pain in mammals. The analgetic utility is demonstrated in the phenyl Analgesia production is achieved when the present ethanobenzazepines are administered to a subject requiring such treatment as an effective oral, parenteral or intravenous dose of from 0.01 to 100 mg kg of body weight per day. A particularly effective amount is about 25 mg kg of body weight per day. It is to be understood, however, that for any particular subject, specific dosage regimens should be adjusted according to the individual need and the professional judgement of the person administering or supervising the administration of the aforesaid compound. It is to be further understood tht the dosages set forth herein are exemplary only and that they do not, to any extent, limit the scope or practice of the invention. Effective amounts of the compounds of the present invention may be administered to a subject by any one of the several methods, for example, orally as in capsules or tablets, parenterally in the form of sterile solutions or suspensions, and in some cases intravenously in the form of sterile solutions. The 1,4 ethanobenzazepines of the present invention, while effective themselves, may be formulated and administered in the form of their pharmaceutically acceptable addition salts for purposes of stability, convenience or crystallization, increased solubility and the like. Preferred pharmaceutically acceptable addition salts include salts of mineral acids, for example, hydrochloric acid, sulfuric acid, nitric acid and the like, salts of monobasic carboxylic acids such as, for example, acetic acid, propionic acid and the like, salts of dibasic carboxylic acids such as, for example, maleic acid, fumaric acid and the like, and salts of tribasic carboxylic acids such as, for example, carboxysuccinic acid, citric acid and the like. Effective quantities of the compounds of the invention may be administered orally, for example, with an inert diluent or with an edible carrier. They may be enclosed in gelatin capsules or compressed into tablets. For the purposes of oral therapeutic administration, the aforesaid compounds may be incorporated with an excipient and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These preparations should contain at least 0.5 of active compound, but may be varied depending upon the particular form and may conveniently be between 4 to about 70 of the weight of the unit. The amount of active compound in such composition is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 1.0 300 milligrams of the active compound. The tablets, pills, capsules, troches and the like may also contain the following ingredients a binder such as microcrystalline cellulose, gum tragacanth or gelatine an excipient such as starch or lactose, a disintegrating agent such as alginic acid, corn starch and the like a lubricant such as magnesium stearate a glidant such as colloidal silicon dioxide and a sweetening agent such as sucrose or saccharin, or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring may be added. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as a fatty oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings and flavors. Materials used in preparing these various compositions should be pharmaceutically pure and non toxic in the amounts used. For the purpose of parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1 of active compound, but may be varied between 0.5 and about 50 of the weight thereof. The amount of active compounds in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.5 to 100 milligrams of active compound. The solutions or suspensions may also include the following components a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents antibacterial agents such as benzyl alcohol or methyl parabens antioxidants such as ascorbic acid or sodium bisulfite chelating agents such as ethylenediaminetetraacetic acid buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as socium chloride or dextrose. The parental preparation can be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic. The following examples are for illustrative purposes only and are not to be construed as limiting the invention. To a stirred suspension of 100 g of 1 acetyl 4 piperidine carboxylic acid chloride in 500 ml of 1,4 difluorobenzene was added in aliquots, 211 g of anhydrous aluminum chloride. The mixture was stirred at reflux under nitrogen for 3 hrs and allowed to cool to room temperature. The mixture was poured into ice and extracted twice with ethyl acetate. The extracts were washed with saturated sodium bicarbonate solution and dried over anhydrous potassium carbonate. Filtration followed by evaporation of the solvent provided an oil which crystallized on standing. The solid was washed with cyclohexane and dried to provide 73.3 g 52.1 of 1 acetyl 4 2,5 difluorobenzoyl piperidine mp 82 87 C. Recrystallization from a mixture of isopropyl alcohol, diisopropyl ether and hexane provided product with mp 93 95 C. To a stirred solution of 11.2 g of 1 acetyl 4 2,5 di fluorobenzoyl piperidine in 225 ml of glacial acetic acid was added dropwise over 0.5 hr a solution of 13.5 ml 42.1 g of bromine in 115 ml of glacial acetic acid at a rate such that the temperature remained between 10 12 C. The mixture was stirred for an additional 10 15 mins, poured into water, extracted twice with ethyl acetate, and the solvent evaporated to provide an oil. The oil was dissolved in ethyl acetate, washed with saturated sodium bicarbonate solution, dried over anhydrous magnesium sulfate, filtered, and the solvent evaporated to provide product as an oil. To a stirred solution of 194.5 g 1.70 mol of 1,4 difluorobenzene in 2 of dry tetrahydrofuran at 60 C was added dropwise over 45 mins 1.70 mol 2.2 M in hexane of n butyllithium at a rate such that the temperature remained below 55 C. The reaction mixture was stirred for 45 mins at below 50 C and 1.5 hr at 50 C to 45 C. The solution was then cooled to 60 C and a solution of 230 g of N methylformanilide in 300 ml of tetrahydrofuran was added dropwise over 30 mins. The mixture was stirred for 1 hr at 50 C and allowed to warm to 30 C over 15 mins. The mixture was then poured into ice water, neutralized pH 6 7 with 10 sulfuric acid and extracted three times with hexane. The extracts were washed once with 1N sulfuric acid, once with saturated sodium chloride solution and concentrated to an oil. Distillation at 64 65 C 20 mm provided 187.5g 77.5 of product. To 25.0 g of trimethylsilylcyanide was added a large spatula of zinc iodide. To the stirred mixture was added dropwise 32.6 g of 2,5 difluorobenzaldehyde with external cooling at a rate such that the temperature rose to 65 C. The mixture was stirred 4 hr at 95 C. Distillation at 75 0.1 mm provided 41.2 g 75.6 of product. To a stirred solution of sodium methoxide, prepared from 3.54 g of sodium spheres in 110 ml dry 3A molecular sieves methanol, was added dropwise a solution of 9.56 g of 1 acetyl 4 bromo 2,5 difluorobenzoyl piperidine in 20 ml of methanol. The solution was stirred at reflux for 1 hr, allowed to cool to room temperature, poured into ice water, extracted twice with ether and the extracts were dried over anhydrous potassium carbonate. Filtration followed by evaporation of the solvent provided 6.4 g of 6 acetyl 2 2,5 difluorophenyl 2 methoxy 6 azaspiro 2,5 octane as an oil. To 6.4 g of 6 acetyl 2 2,5 difluorophenyl 2 methoxy 1 oxa 6 azaspiro 2,5 octane was added a solution of 8.1 ml of conc hydrochloric acid in 42 ml of ethanol. The mixture was stirred at room temperature for 15 mins, poured into ice water and extracted twice with ethyl acetate. The extracts were washed with saturated sodium bicarbonate solution, saturated sodium chloride solution and dried over anydrous potassium carbonate. Filtration followed by evaporation of solvent provided 4.70 g of an oil which crystallized on drying under vacuum for 48 hours. Recrystallization from ethyl acetate provided 3.11 g 40 of 1 acetyl 4 2,5 difluorobenzoyl 4 hydroxy piperidine, mp 118 120 C. A suspension of 5.66 g of 1 acetyl 4 2,5 difluorobenzoyl 4 hydroxypiperidine in 10 ml of 6N hydrochloric acid was stirred at reflux, under nitrogen for 3.5 hrs. The reaction mixture was allowed to cool to 0 C whereupon a solid separated. The solid was collected, washed with ice cold acetone and dried to give 4.4 g 80 of product, mp 191 193 C. A solution of lithiumdiisopropylamide in tetrahydrofuran was prepared, under nitrogen, by addition of 181 ml of 2.2 N solution of n butyllithium in hexane to a solution of 56 ml of diisopropylamine in ca. 400 ml of dry tetrahydrofuran freshly distilled from lithium aluminumhydride at 70 C and subsequent warming up to 20 C. The lithiumdiisopropylamide solution was then cooled to 74 C and 85 g ofα trimethylsilyloxy 2 fluoro benzeneacetonitrile were added dropwise so that the temperature remained between 74 C and 70 C. The resulting solution was stirred for 1 hr at 74 C. A mixture of 53.6 g of 1 acetyl 4 piperidone and 60 ml of tetrahydrofuran was then added at 70 C to 60 C. The resulting mixture was allowed to warm up very slowly ca. 20 hrs to 0 C. After stirring for two additional hrs at 0 C, the mixture was poured into a stirred mixture 0.5 l of sat ammonium chloride solution, 0.5 kg of ice and 1 liter of ethyl acetate. The layers were separated and the aqueous layer extracted twice with ethyl acetate. The combined organic layers were washed with dilute potassium carbonate solution, brine, dried over anhydrous potassium carbonate, filtered, and evaporated to provide 114 g 89 of 1 acetyl 4 2 fluorobenzoyl 4 trimethylsilyloxypiperidine as a resin. The resin was dissolved in 600 ml of methanol and 600 ml of 1.2 N hydrochloric acid was added with vigorous stirring. Stirring was continued for 20 hrs at room temperature. The resulting solution was stirred into brine and extracted thrice with ethyl acetate. The extracts were washed with dilute potassium carbonate solution, dried over anhydrous sodium sulfate and evaporated, finally at high vacuum, to yield a solid. Trituration with hot ethyl acetate provided 29.4 g of analytically pure product, mp 144 146 C. From the mother liquor another 28.1 g of product was obtained by addition of hexane. Total yield 57.5 g 57 . A mixture of 13.3 g of 1 acetyl 4 2 fluorobenzoyl 4 hydroxypiperidine and 20 ml of 6N hydrochloric acid was stirred at reflux under nitrogen for 4 hrs. The reaction mixture was allowed to cool and poured onto ca. 100 g of ice. Methylene chloride was added, and the separated aqueous layer was made strongly basic by means of 15 sodium hydroxide solution. The aqueous layer was extracted three times with 80 ml of methylene chloride. The extracts were dried over anhydrous potassium carbonate, filtered and evaporated provide anhydrous 9.5 g 85 of product, mp 133 135 C. A mixture of 11.0 g of 4 2 fluorobenzoyl 4 hydroxy piperidine, 10.1 g of milled anhydrous potassium carbonate, 330 ml of n butyl acetate and 20 ml of dimethylformamide was stirred at reflux under nitrogen for ca. 26 hrs. The hot reaction mixture was filtered. The filter cake was washed with hot chloroform and the filtrates evaporated to yield a solid. Recrystallization from ethyl acetate provided 9.0 g 90 of product, mp 134 136 C. A suspension of 9.86 g of 4 2,5 difluorobenzoyl 4 hydroxypiperidine, 250 ml of n butyl acetate, 16.3 g of anhydrous potassium carbonate and 0.9 g of potassium iodide was stirred at reflux for 40 hrs. The mixture was allowed to cool to room temperature and poured into ice water. The mixture was extracted twice with ether, washed with water and saturated sodium chloride solution and dried over anhydrous potassium carbonate. Filtration followed by evaporation of the solvent provided an oil. The oil was filtered through alumnia eluent ether . Evaporation of solvent provided an oil which was further purified by high pressure liquid chromatography using a Waters Prep 500 apparatus eluent 3 methanol dichloromethane . Concentration provided 5.33 g 58.9 of 1,4 ethano 7 fluoro 4 hydroxy 2,3,4,5 tetrahydro 5H 1 benzazepin 5 one, mp 102 104 C. Sodium borohydride 1.2 g was added to a stirred solution of 4.06 g of 1,4 ethano 4 hydroxy 2,3,4,5 tetrahydro 5H 1 benzazepine 5 one in a mixture of 50 ml of methanol and 10 ml of tetrahydrofuran at room temperature. The reaction mixture was stirred overnight at ambient temperature and evaporated to dryness. The residue was treated with 150 ml of almost saturated potassium carbonate solution and the resulting mixture extracted with ca. 300 ml of chloroform by means of continuous extraction for 20 hrs. The extract was dried over anhydrous sodium sulfate and the solvent evaporated to give 4.5 g of a solid. Recrystallization from chloroform hexane provided 2.7 g 66 of 1,4 ethano 4,5 dihydroxy 2,3,4,5 tetrahydro 5H 1 benzazepine, mp 169 170 C. Sodium borohydride powder 1.7 g was added in one portion to a stirred solution of 5.1 g of 1,4 ethano 7 fluoro 4 hydroxy 2,3,4,5 tetrahydro 1H 1 benzazepine 5 one in a mixture of 80 ml of methanol and 5 ml of tetrahydrofuran. The reaction mixture was stirred overnight at room temperature, made strongly acidic by dropwise addition of concentrated hydrochloric acid and evaporated to dryness. The residue was stirred with excess potassium carbonate solution and the cloudy mixture extracted twice with ethyl acetate. The organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered and evaporated to yield a solid. Recrystallization from ca. 30 ml of chloroform provided 2.6 g 51 of product, mp 138 140 C. A suspension of 4.06 g of 4 hydroxy 1,4 ethano 2,3,4,5 tetrahydro 1H 1 benzazepine 5 one and 0.5 g of 4 dimethylamino pyridine in 15 ml of dry dichloromethane was prepared under nitrogen. Triethylamine 3.03 g was added followed by addition of 4.3 g of acetic anhydride. The reaction mixture was stirred overnight at ambient temperature under nitrogen. The solvent was evaporated under reduced pressure, and the residue was dissolved in a mixture of dichloromethane and methanol. Purification of the desired product by means of flash chromatography silica gel, 1 methanol dichloromethane gave an oil. Treatment with hexane diisopropylether provided, after cooling and seeding, 3.0 g 61 of product, mp 88 90 C. A mixture of 4.42 g of 4 hydroxy 1,4 ethano 7 fluoro 2,3,4,5 tetrahydro 1H 1 benzazepine 4 one, 0.5 g of 4 dimethyl aminopyridine and 17 ml of dry dihloromethane was prepared under nitrogen. Triethylamine 3.03 g and 4.3 g of acetic acid were added at room temperature. The resultant solution was stirred overnight at room temperature under nitrogen. Removal of solvent under reduced pressure and separation of the desired product by means of flash chromatography on silica gel 1 methanol dichloromethane provided a solid. Recrystallization from diisopropyl ether provided 3.6 g 68.4 of product, mp 135 136 C. To a stirred mixture of 4.1 g of 1,4 ethano 4,5 dihydroxy 2,3,4,5 tetrahydro 5H 1 benzazepine 50 ml of anhydrous tetrahydrofuran and 5 ml of acetaldehyde was added 3.0 ml of boron trifluoride etherate under nitrogen. An additional 8 ml of acetaldehyde diethylacetal and 3 ml of boron trifluoride etherate was added, and the solution was stirred for one day at room temperature. The reaction mixture was poured into an excess of a half saturated aqueous potassium carbonate solution. Extraction with ether, drying of the organic layers over anhydrous sodium sulfate, evaporation of solvent and purification of the oil by means of flash chromatography silica gel, 3 methanol dichloro methane 0.1 aqueous ammonia, eluent gave 3.8 g 82 of product as the free base. A 3.5 g portion of the free base was dissolved in ether and a stochiometric amount of an ethereal solution of maleic acid was added. Filtration, washing with ether and drying under high vaccum provided 3.9 g 56 of product, mp 134 137 C. A mixture of 3.08 g of 1,4 ethano 4,5 dihydroxy 2,3,4,5 tetrahydro 5H 1 benzazepine, 50 ml of anhydrous tetrahydrofuran, 7 ml of propionaldehyde diethylacetal and 5.2 ml of boron trifluoride etherate was stirred under nitrogen for 2 hrs at room temperature and for 1.5 hrs at 40 C. The reaction mixture was poured into excess ice cold aqueous potassium carbonate solution and extracted twice with a mixture of ether and ethyl acetate. The extracts were washed with brine, dried and evaporated to give an oil. Purification by means of flash chromatography provided 2.1 g 57 of product as an oil. The hydrochloride was prepared by dissolving the oil in anhydrous ether and adding dropwise ethereal hydrochloric aicd. Filtration and drying yielded 2.1 g 50 of product, mp 235 237 C dec . To a solution of 3.08 g of 1,4 ethano 4,5 dihydroxy 2,3,4,5 tetrahydro 5H 1 benzazepine in a mixture of 50 ml of dry tetrahydrofuran and 4 ml of 2,2 dimethoxypropane was added 3.7 ml of distilled boron trifluoride ethereate dropwise with vigorous stirring under an atmosphere of nitrogen. Stirring was continued at room temperature for 2.5 hrs. The reaction mixture was poured into 200 ml of ice cold half saturated aqueous potassium carbonate solution. Extraction with ether 3x , washing with brine and drying over sodium sulfate and evaporation of solvent provided 3.5 g of a solid. Recrystallization from diisopropyl ether gave 2.5 g 67 of product, mp 135 137 C. A solution of 3.08 g of 1,4 ethano 4,5 dihydroxy 2,3,4,5 tetrahydro 1H 1 benzazepine and 3.04 g of benzaldehyde dimethyl acetal in 50 ml of anhydrous tetrahydrofuran was prepared under nitrogen. Boron trifluoride etherate 3.8 ml was added with vigorous stirring at 35 C over a period of a few mins. The reaction mixture was stirred for 2 hrs at 50 C and then poured into a stirred ice cold dilute potassium carbonate solution. The product was extracted several times with ether. Drying over anhydrous sodium sulfate and removal of the solvent under reduced pressure provided a solid. Recrystallization from diisopropyl ether yielded 2.4 g 54.5 of product, mp 144 146 C. To a solution of 3.7 g of 1,4 ethano 4,5 dihydroxy 7 fluoro 2,3,4,5 tetrahydro 1H 1 benzazepine in 50 ml of dry tetrahydrofuran, 2.2 ml of boron trifluoride etherate was added dropwise, with stirring, at room temperature, under nitrogen. To the mixture, 5 ml of acetaldehyde was added. After stirring for ca. 16 hrs, 1.2 ml of freshly distilled boron trifluoride etherate and of ca. 2 ml of acetaldehyde diethylacetal were added, and the solution was stirred for ca. two hrs at 40 C. The reaction mixture was then stirred into a mixture of 200 ml of saturated sodium bicarbonate solution and a few ml of saturated potassium carbonate solution. Extraction with ethyl ether twice and ethyl acetate, washing of the combined organic extracts with brine, drying over anhydrous potassium carbonate and evaporation of the solvent provided 4.8 g of a semi solid. Purification by means of flash chromatography silica gel, 1 3 methanol dichloromethane followed by recrystallization from hexane diisopropyl ether gave 1.8 g 44 of product, mp 103 107 C. To a solution of 2.70 g of 1,4 ethano 4,5 dihydroxy 7 fluoro 2,3,4,5 tetrahydro 1H 1 benzazepine in 40 ml of anhydrous tetrahydrofuran was added 1.6 ml of boron trifluoride etherate with vigorous stirring at room temperature under nitrogen. To the mixture, 2 ml of acetone was added and the mixture stirred for 16 hrs. Boron trifluoride etherate 1.3 ml was added, followed by 4 ml of 2,2 dimethoxypropane. After stirring for about 30 mins at 35 C, the solution was poured into a mixture of 100 ml of saturated sodium bicarbonate solution, a few ml of saturated potassium carbonate solution and 50 ml of ether. The aqueous layer was washed twice with ether. The ether layers were dried over anhydrous sodium sulfate and evaporated to dryness to give a solid. Recrystallization from hexane diisopropyl ether provided 2.5 g 79 of product, mp 120 122 C. A solution of 3.35 g of 7 fluoro 1,4 ethano 4,5 dihydroxy 2,3,4,5 tetrahydro 1H 1 benzazepine and 3.04 g of benzaldehyde dimethyl acetal in 50 ml of anhydrous tetrahydrofuran was prepared under nitrogen. Boron trifluoride etherate 3.8 ml was added with vigorous stirring at room temperature over a period of a few mins. The solution was stirred for 2 hrs, poured into a stirred ice cold dilute potassium carbonate solution, and extracted several times with ether. Drying the ether extracts over anhydrous sodium sulfate and evaporation of the solvent under high vacuum provided an oil, which crystallized on standing. Recrystallization from diisopropyl ether yielded 2.4 g 51 of product, mp 128 130 C.